AbCellera Biologics Inc.
(NASDAQ:ABCL) announced positive top-line Phase 2 results from its Phase 1/2 trial evaluating ABCL635.
The investigational neurokinin 3 receptor antagonist antibody is designed as a long-acting, non-hormonal subcutaneous treatment for moderate-to-severe vasomotor symptoms, or hot flashes, associated with menopause.
A single dose produced statistically significant reductions in both the frequency and severity of hot flashes at four weeks compared with placebo.
The four-week data for the Phase 2 study of ABCL635 demonstrate a new efficacy benchmark for the reduction of hot flashes both in frequency and severity, as well as improvements in sleep, said JoAnn Pinkerton, Women’s Midlife Professor of Obstetrics and Gynecology at the University of Virginia School of Medicine.
